Vertex And CRISPR Therapeutics Enter Licensing Agreement To Discover And Develop Gene Therapies For DMD And DM1; Vertex To Acquire Exonics For $245M Plus Potential Milestones, CRISPR To Receive Upfront Payment Of $175M
Benzinga Newsdesk